Effect Of PPARγ Agonist Rosiglitazone On Stable Of Atherosclerotic Plaque

Objective: We had found that PPARγ has a good effect on the development of atherosclerosis,but the mechanism of this effect is no full understood.The macrophages apoptosis in the atherosclerotic plaque have a great role on the stable of plaque. We supposed PPARy agonist can interfere macrophages apoptosis in the atherosclerotic plaque.Hence,PPARγ agonist may have a benefit on the atherosclerotic plaque. Method: To prepare the atherosclerotic models of white rabbits using forge rich in fat. Two groups were divided in random: Rosiglitazone group and control group. The number of macrophages in the atherosclerotic plaque was measured with mouse anti rabbit macrophage antibody,RAM-11.The rate of apoptosis in macrophages was detected by TUNEL .And the presence of the caspase3 protein was detected byimmunohistochemical technique.Result: The thickness of the plaque is less in the treatment group than the placebo ( P<0.05) . The number of macrophages inplaque of Rosiglitazone group was lower than control group( P<0.05 ) .The rate of apoptosis in macrophages inRosiglitazone group was lower than control group ( P<0.05). thepositive rate of caspase3 protein was less than control group(P<0.05) .Conclusion: PPARy can decrease the thickness of the atherosclerotic plaque .PPARy inhibits apoptosis of macrophages in plaque of rabbits and stabilize plaque.This effect may be reached by the decreasing expression of caspase3.